GSK wins China approval for Exdensur to treat nasal polyps

China's NMPA approved GSK's Exdensur (depemokimab) as an add-on therapy for adult chronic rhinosinusitis with nasal polyps (CRSwNP) where systemic corticosteroids and/or surgery are inadequate. Phase III ANCHOR-1 and ANCHOR-2 showed nasal polyp score improvements at 52 weeks of -0.7 (p<0.001) and -0.6 (p=0.004), with depemokimab arms of 143 and 129 patients vs placebo arms of 128 and 128; dosing is every six months (two doses a year). The approval builds on prior severe asthma approvals and modestly expands GSK's respiratory franchise in China, likely producing a modest positive reaction in the company's stock.

Analysis

This approval should be read as a distribution and adoption shock rather than a single product event — the real value hinges on payer formulary decisions, hospital pathway adoption and how quickly prescriptions convert from incumbent biologics. Expect the first 6–12 months to be driven by private hospital and specialist clinic uptake in higher-reimbursement metros; national reimbursement and broad retail penetration will take 12–36 months and determine peak sales.

A meaningful second-order winner is outsourced biologics manufacturing and sterile fill/finish capacity: any accelerated uptake will stress existing CDMO slots and could push incremental COGS and lead times higher, creating short windows where margin upside is limited by supply constraints. Conversely, incumbents with entrenched hospital-administered formulations could see revenue erosion from a lower-frequency, potentially self-administered alternative, pressuring ASPs in specialty channels.

Tail risks that could reverse the trade are straightforward and front-loaded: an unfavorable national reimbursement decision, an emergent safety or effectiveness signal in real-world data, or a competitor label extension priced aggressively. Monitor three near-term catalysts — payer negotiations, first 6-month real-world adherence metrics, and CDMO capacity announcements — to convert this regulatory event into an investable thesis over the 6–24 month horizon.

Key Decisions for Investors

• Buy GSK (GSK) 12-month call spread sized ~2% NAV (bullish exposure with capped cost). Target 25–40% upside if uptake accelerates in first 12 months; max loss = premium. Monitor reimbursement outcomes every quarter and take profits on announcement of national formulary inclusion.
• Pair trade: Long GSK (equal notional) / Short REGN or SNY (Dupixent co-marketer) for 9–18 months to express share-shift risk in CRSwNP/asthma markets. Size at 1.5% NAV each leg to keep idiosyncratic risk balanced; downside if competitors defend with price or label expansions.
• Tactical long on Catalent (CTLT) or selected CDMOs, 6–12 month horizon, 1% NAV — play potential spot shortages and higher utilization leading to upside to contract pricing. Tail risk: delayed commercial-scale transfers or capex that eases constraints within 12–18 months.
• Hedge / risk management: buy 12-month GSK puts or set a 20–30% stop on the equity leg ahead of national reimbursement decisions and the first real-world safety readouts — these are binary catalysts that can erase early upside.